Clinical research company Medpace Holdings (NASDAQ:MEDP) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 26.5% year on year to $706.6 mil...
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 26.5% year on y...
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting earnings this Wednesday after the bell. Here’s what to look for. Medpace beat anal...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...
Over the past six months, Medpace’s shares (currently trading at $483.21) have posted a disappointing 11.2% loss while the S&P 500 was down 5.5%. This might ...
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance pro...
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development inputs & services stocks fared in Q4, starting with Medpace (NASDAQ:MEDP).
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court ruled the previous week that the president could not use the International Emergency Economic Powers Act (IEEPA) for such duties, a decision that had initially sent markets higher. However, the administration invoked a different authority, the Trade Act of 1974, to impose a 15% global tariff for up to 150 days. The rapid reimposition of trade barriers creates significant uncertainty for companies across multiple sectors that depend on international supply chains and global trade. Investors are now weighing the potential impact of these new duties on corporate earnings and broader economic activity.
Understanding the real drivers behind dramatic stock swings can help investors avoid costly mistakes and spot opportunities hidden beneath the headlines.
Medpace’s fourth quarter was marked by robust top-line growth and a significant year-over-year increase in revenue, but the market responded negatively, likely due to rising cancellations and margin pressure. CEO August Troendle acknowledged that “cancellations were elevated again in Q4,” with the highest backlog cancellations in over a year, particularly impacting the metabolic therapeutic area. This uptick in cancellations and a shift in business mix put downward pressure on operating margin, which declined compared to the prior year. Management described the business environment as “adequate and headed in the right direction,” but did not anticipate the spike in cancellations.
